Factor This Power Engineering
Live Events
DTECH® Events
POWERGENâ¢
Calendar
Webinars
Podcasts
Contribute Content
Solar
Community
Residential
Utility Scale
Wind Power
Offshore
Turbines & Equipment
Power Grid
Distribution
Grid Modernization
Microgrids
Outage Management
Smart Grids
Transmission
Hydropower
Dams & Civil Structures
Small Hydropower
Technology & Equipment
Tidal & Wave Energy
Energy Storage
Battery
Long Duration
Pumped Storage
Business
Finance
Policy & Regulation
Project Development
Tariffs
Electric Vehicles
EV Charging
Vehicle to Grid
Subscribe
Solar
Community
Residential
Utility Scale
Wind Power
Offshore
Turbines & Equipment
Power Grid
Distribution
Grid Modernization
Microgrids
Outage Management
Transmission
Smart Grids
Hydropower
Dams & Civil Structures
Small Hydro
Technology & Equipment
Tidal & Wave Energy
Energy Storage
Battery
Long Duration
Pumped Storage
Business
Finance
Policy & Regulation
Electric Vehicles
EV Charging
Vehicle to Grid
Factor This: Power Engineering
Live Events
DISTRIBUTECH®
Podcasts
Webinars
Calendar
Contribute Content
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
EL&P Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
COMPASS Pathways Plc - American Depository Shares
(NQ:
CMPS
)
5.080
-0.120 (-2.31%)
Streaming Delayed Price
Updated: 10:52 AM EST, Nov 21, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about COMPASS Pathways Plc - American Depository Shares
< Previous
1
2
...
6
7
8
9
10
11
12
13
14
...
30
31
Next >
May Summary Of Largest Psychedelic Compound-Based Drug Stock Performances
↗
June 01, 2023
Only two of the seven largest psychedelic compound-based drug stocks tracked, advanced in May.
Via
Talk Markets
Psyched: LSD Microdosing For Depression, DMT For Anxiety, MDMA Octopuses And More
↗
May 31, 2023
Microdosing LSD For Major Depression Treatment Seeks Further Clinical Validation Via New Study Australian psychedelics company MindBio Therapeutics Corp. was granted approval by both the Ethics...
Via
Benzinga
Numinus' Clinical Site Joins Compass' Phase 3 Program On Psilocybin Therapy For TRD
↗
May 30, 2023
Numinus Wellness Inc.’s (OTCMKTS: NUMIF) wholly-owned contract research organization Cedar Clinical Research has commenced a new study on COMPASS Pathways’ (NASDAQ: CMPS) psilocybin therapy for...
Via
Benzinga
Trial Gives Cancer Patients 18 Months Of Robust Benefits After One Psilocybin Session
↗
May 26, 2023
Positive long-term follow-up data from Sunstone Therapies’ investigator-initiated Phase 2 study assessing COMPASS Pathways’ (NASDAQ: CMPS) synthetic psilocybin COMP360 paired with psychological support...
Via
Benzinga
Link Between Cancer And Psilocybin: Research On This Palliative Promise
↗
May 22, 2023
The use of psychedelic-assisted therapy to treat cancer-related conditions has come a long way.
Via
Benzinga
Expert Ratings for Compass Pathways
↗
May 11, 2023
Via
Benzinga
Compass Pathways: Q1 Earnings Insights
↗
May 11, 2023
Via
Benzinga
Earnings Preview: Compass Pathways
↗
May 10, 2023
Via
Benzinga
Psyched: $20M Research Fund, LSD Microdosing For Cancer, MEAI Enters Clinical Stage, Reform Update & More
↗
May 15, 2023
Researchers At Johns Hopkins Get $20M Fund Prompted By Longtime Psychedelics Scientist Johns Hopkins University academics received a boost in funding thanks to the recently launched Roland R. Griffiths...
Via
Benzinga
COMPASS Pathways Reports Q1 2023: Financials, Commercial Groundwork And Ongoing Phase 3 Trials
↗
May 11, 2023
Mental healthcare biotech company advancing psilocybin therapy COMPASS Pathways plc (NASDAQ: CMPS) reported its financial results for the first quarter 2023 ended March 31, 2023 and updated on recent...
Via
Benzinga
Atai Life Sciences Q1 2023 Results, Pipeline Update On DMT And Psilocybin Clinical Trials
↗
May 11, 2023
Clinical-stage biopharma company atai Life Sciences (NASDAQ: ATAI) reported the financial results for its first quarter ended March 31, 2023, and provided the period’s business highlights. Consolidated...
Via
Benzinga
Compass Pathways Plc (CMPS) Q1 2023 Earnings Call Transcript
↗
May 11, 2023
CMPS earnings call for the period ending March 31, 2023.
Via
The Motley Fool
COMPASS Pathways Announces First Quarter 2023 Financial Results and Business Highlights
May 11, 2023
From
COMPASS Pathways
Via
GlobeNewswire
Psyched: Psychedelics Reimbursement, Amanita Muscaria Boom, $53M Material Breach Lawsuit & More
↗
May 08, 2023
EXCLUSIVE: AMA Moves Toward Psychedelic Therapy Reimbursement, Filing A Gap In Regulations
Via
Benzinga
This Regulatory Change Means Psychedelic Stocks Are One Step Closer to Being a Buy. Here's Why
↗
May 06, 2023
Another piece of the regulatory puzzle fell into place, but there are plenty more.
Via
The Motley Fool
EXCLUSIVE: AMA Moves Toward Psychedelic Therapy Reimbursement, Filing A Gap In Regulations
↗
May 02, 2023
The American Medical Association (AMA) is expected to issue the first code for psychedelic therapy reimbursement, following Tuesday's approval of a joint application submitted by MAPS PBC and COMPASS...
Via
Benzinga
American Medical Association to Issue First New Code for Psychedelic Therapies
May 02, 2023
COMPASS Pathways and MAPS PBC submitted joint application for new code to facilitate access to psychedelic therapy in the US, if approved
From
COMPASS Pathways
Via
GlobeNewswire
April Psychedelic Drug Stocks Recap: The Ups And Downs
↗
April 30, 2023
Via
Talk Markets
Seelos Therapeutics, Compass Pathways Among Top Psychedelic Movers Of Today
↗
April 21, 2023
Via
Benzinga
Seelos Therapeutics, ATAI Life Sciences Among Top Psychedelic Movers Of Today
↗
April 20, 2023
Via
Benzinga
After Falling 60% in 1 Year, Is Atai Life Sciences Stock Still a Buy?
↗
April 20, 2023
Atai's stock is hurting, but its pipeline is still packed with promising programs.
Via
The Motley Fool
Cybin, Mind Medicine Among Top Psychedelic Movers Of Today
↗
April 19, 2023
Via
Benzinga
Psychedelic Stock Gainers And Losers From April 18, 2023
↗
April 18, 2023
Via
Benzinga
Psychedelic Stock Gainers And Losers From April 17, 2023
↗
April 17, 2023
Via
Benzinga
5 Short Squeeze Stocks To Watch: Getty Images, PaxMedica, A Mental Health Care Company And More
↗
April 17, 2023
Potential short squeeze plays gained steam in 2021, continued through 2022, and remain a focus of new traders looking for the next huge move. High short interest and high cost to borrow are among the...
Via
Benzinga
Psilocybin Therapy Continues To Show Positive Outcomes For Cancer And Major Depression Disorder
↗
April 14, 2023
Results from an advanced clinical trial assessing psilocybin-assisted therapy for patients with cancer and Major Depressive Disorder (MDD) conducted by oncology center Sunstone Therapies were published...
Via
Benzinga
ATAI Life Sciences, Seelos Therapeutics Among Top Psychedelic Movers Of Today
↗
April 14, 2023
Via
Benzinga
Psychedelic Stock Gainers And Losers From April 13, 2023
↗
April 13, 2023
Via
Benzinga
EXCLUSIVE: Investing In The Unique Growth Market Of Psychedelics
↗
April 13, 2023
The global psychedelics market of drugs such as psilocybin, ketamine and LSD is booming and there are plenty of ways to get involved in the space.
Via
Benzinga
Psychedelic Stock Gainers And Losers From April 12, 2023
↗
April 12, 2023
Via
Benzinga
< Previous
1
2
...
6
7
8
9
10
11
12
13
14
...
30
31
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
